The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.
Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.
In this Science Surgery post Millie asks: ‘Why doesn’t the immune system attack cancer cells?’ The short answer is it does! But sometimes it needs a helping hand from exciting new treatments.
Our new research partnership is exploring common ground between arthritis and cancer, which could bring benefits to patients on both sides.